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Pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma (PDAC) is a devastating disease with low survival rates. Current therapeutic
treatments have very poor response rates due to the high inherent chemoresistance of the pancreatic-cancer
cells. Recent studies have suggested that the receptor for advanced glycation end products (RAGE) and its
S100 protein ligands play important roles in the progression of PDAC. We will discuss the potential role of
S100 proteins and their receptor, RAGE, in the development and progression of pancreatic cancer.
© 2015 Elsevier B.V. All rights reserved.1. Pancreatic ductal adenocarcinoma
Pancreatic cancer is the fourth leading cause of cancer death in the
United States with fewer than 6% of patients surviving more than 5
years. Among all pancreatic cancers, the most frequent (85%) one is
pancreatic ductal adenocarcinoma (PDAC). PDAC arises from epithelial
cells in small pancreatic ducts which alter their morphologies and
progress into cells with invasive properties. Several important steps
have been identiﬁed during disease progression (Fig. 1). The ﬁrst step
is the formation of pancreatic intraepithelial neoplasia (PanIN), or
lesions, which progresses from stages 1A, 1B and 2 to stage 3, based
on the degree of architectural and nuclear atypia, before reaching an
invasive stage (Fig. 1). The lesions that progress to the invasive stage
are the sites ofmultiple genetic and epigenetic alterations. For example,
mutations in theKRAS gene have been suggested to drive early events in
the formation of PanIN, whereas mutations in the P16INK4a, P53 and
SMAD4 genes have been associatedwith later events and the acquisition
of invasiveness (Fig. 1) [1].
For many years, pancreatic-cancer patients with metastatic disease
onlyhadone chemotherapeutic option, amonotherapywith gemcitabine,
whichwas the ﬁrst drug to be FDA-approved for the treatment of pancre-
atic cancer.However, newcombination therapies have recently been test-
ed in clinical trials and have led to improved overall survival rates. These
new treatment options include a combination of gemcitabine with the
mitotic inhibitor paclitaxel, which is formulated as albumin-based nano-
particles. Another option consists of a multi-drug combination called
folﬁrinox, which includes two cytotoxic drugs, 5-ﬂuorouracil andoxaliplatin; the topoisomerase inhibitor irinotecan; and an adjuvant
drug, folinic acid [1]. Despite showing improved overall response rates,
these new combinations are also accompanied with toxic adverse effects,
such as severe cytopenias, diarrhea and neutropenic fevers, which can
limit their usage in patients [1].
Despite the recent advances with combination-drug therapies,
pancreatic cancer still remains difﬁcult to treat because of the pancreatic
tumors' high chemoresistance, resulting from molecular mechanisms,
such as deﬁciencies in nucleoside transporters or deoxycytidine kinase
activity, as well as from mechanical properties caused by strong
desmoplasia, poor vascularization and high interstitial ﬂuid pressure in
the tumor [1]. To overcome the chemoresistance problem, novel thera-
peutic strategies are currently being tested in pre-clinical and clinical tri-
als; these studies focus on improving the drug delivery to and speciﬁc
targeting of both the tumor cells and the tumor'smicro-environment [1].
Recent studies suggest that the receptor for advanced glycation end
products (RAGE) could be a key player in the progression of pancreatic
cancer and could be a potential therapeutic target (Fig. 1) [2]. Among
other ligands, RAGE can be activated by several members of the S100
protein family [3]. We will discuss evidence supporting a role for
RAGE and its S100 protein ligands in the progression of pancreatic
ductal adenocarcinoma.
2. The receptor for advanced glycation end products (RAGE)
2.1. The physiological role of RAGE
RAGE is a cell-surface receptor from the large family of
immunoglobulin-like receptors. Although RAGE is not essential for
life, in vivo studies suggest that RAGE contributes to auditory sensitivity
in mice; RAGE plays a role in certain types of pulmonary ﬁbrosis, innate
Fig. 1. Important stages in the development of pancreatic ductal adenocarcinoma (PDAC).
PDAC arises from genetic and epigenetic changes in epithelial cells of pancreatic ducts.
Four main stages (1A, 1B, 2 and 3) of intraepithelial neoplasia (PanIN), or lesions, have
been described. These lesions can progress into invasive PDAC. Studies have identiﬁed im-
portant genes (KRAS, P16INK4A, P53 and SMAD4) that are responsible for the phenotypic
changes with PDAC. Recent studies have also shown that RAGE expression increases
signiﬁcantly during PDAC progression [2].
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tion and myogenesis following acute skeletal muscle injury. The role of
RAGE on the pancreas' homeostasis is still poorly understood, however,
increasing evidence suggests that RAGE contributes to the progression
of pancreatic ductal adenocarcinoma.
2.2. Ligands of RAGE
RAGE was ﬁrst identiﬁed as a receptor for a class of compounds
named advanced glycation end products (AGEs). AGEs are formed as a
result of the reaction between carbonyl groups of carbohydrates and
amino groups of proteins. AGEs are found in multiple types of disease
tissues, such as cancer tissues, the brain of Alzheimer's disease patients
or the vasculatures of diabetic patients [4].
Besides AGEs, RAGE also binds to other structurally unrelated li-
gands, such as amyloid-formingpeptides and proteins, thehighmobility
group box 1 protein (HMGB1), the complement receptormacrophage-1
antigen (Mac-1) and S100 proteins [3]. In recent years, new types of
RAGE ligands, including the C3a and C1q complement proteins,
phosphatidylserine, heparan sulfate, and DNA and RNAs, have been
identiﬁed.
2.3. RAGE isoforms
Structurally, RAGEbelongs to the immunoglobulin receptor superfam-
ily, with the extracellular part containing three immunoglobulin-like
domains: one variable-like (V) and two constant-like (C) domains. In ad-
dition to this extracellular VC1C2 part, the full-length RAGE isoform also
possesses a short 35-residue-long transmembrane domain that anchors
the receptor to the cell and an intracellular domain (40 amino acids)
that is responsible for signal transduction [5].
Besides full-length RAGE, other isoforms of RAGE that lack speciﬁc
domains, such as the V, transmembrane or intracellular domains, have
been described [6]. An important isoform is the soluble form of RAGE
(sRAGE). sRAGE can be generated through two mechanisms, splicing
events or shedding by proteases [6]. The physiological function of
these non-full-length RAGE isoforms is being debated. The soluble
form of RAGE has been suggested to play the role of a decoy receptor
and to bind to RAGE ligands. However, RAGE is present at picomolar
concentrations in the circulation; this concentration does not allow
RAGE to form complexes with all potential RAGE ligands that may be
present at nanomolar concentrations. Recently, it was suggested
that the soluble form of RAGE could act through the formation of a
non-functional complex with a full-length RAGE isoform [5].2.4. RAGE structure and signaling
At the cell surface, in the absence of ligands, RAGE has been shown to
exist as a homodimer. Binding the ligand to RAGE has been suggested to
trigger the formation of larger oligomeric forms, and several models for
the RAGE/ligand complexes have been proposed [5].
When RAGE is engaged by its ligands, multiple signaling pathways
may be activated in a ligand-dependent manner. These signaling path-
ways include the PI3K/Akt pathway; several mitogen-activated protein
kinase (MAPK) pathways involving Erk1/2, p38, and JNK; and other
pathways involving small GTPases, such as p21-Ras, Rac-1, or cdc42.
RAGE engagement by its ligands often leads to the activation of several
transcription factors, such asNF-κB, AP-1, STAT-3 andCREB. Because the
RAGE gene is under the control of NF-κB, the engagement of RAGE by its
ligands results in ampliﬁed RAGE activation in a positive feedback
loop [4].
2.5. RAGE in pancreatic cancer
Growing evidence suggests that RAGE participates in the progres-
sion of pancreatic cancer. Early studies showed a positive correlation
between the RAGE level and the metastatic properties of several
pancreatic-cancer cells. Later, independent gene-proﬁling studies of
human pancreatic-tumor tissues showed that two RAGE ligands,
S100P and S100A6, were strongly expressed in tumor samples when
compared with the control-tissue samples. Epigenetic modiﬁcations,
such as aberrant gene hypomethylation, of S100P were also associated
with increased tumor progression in pancreatic-tumor tissues. In a
series of studies, the Logdson group demonstrated that blocking the
RAGE/S100P interaction with either a S100P-derived antagonistic
peptide or the small molecule S100P-binding drug cromolyn resulted
in reduced growth, invasiveness and viability for the pancreatic-
cancer cell lines aswell as reduced tumor growth andmetastasis forma-
tion in orthotopic mouse models of pancreatic cancer [7]. The role of
RAGE in PDAC was also strongly supported by the observation that, in
a KRAS mouse model of PDAC, animals lacking RAGE (Pdx1-Cre;
LSL-Kras (G12D/+); RAGE (−/−)) experienced signiﬁcant reductions
in the number of early pancreatic PanIN lesions and in pancreatic-
cancer tumor growth, and exhibited longer median survivals compared
to the control mice [2]. At the molecular level, Kang et al. showed that
RAGE promoted cell survival through increased autophagy and reduced
apoptosis (Fig. 2A). In a different study, these authors demonstrated
that RAGE contributed signiﬁcantly to resistance to chemo- and radio-
therapy through the release of HMGB1 by dying cells, resulting in
sustained activation of RAGE and cell survival through a positive feed-
back loop involving NF-κB (Fig. 2A). The HMGB1−/RAGE axis was
also shown to control the bioenergetics of pancreatic-cancer cells [8].
RAGE signaling from stromal cells could signiﬁcantly contribute to
tumor development. Indeed, RAGE is expressed in many cells that
form the tumor environment, such as endothelial cells, ﬁbroblasts,
myoﬁbroblasts, T cells and myeloid-derived suppressor cells [4].
Among these cells, tumor-associated myoﬁbroblasts have been shown
to be responsible for the desmoplastic reactions that are characteristic
of pancreatic tumors. Because of its expression in both cancer and
stromal cells, RAGE appears to be a promising therapeutic target for
pancreatic cancer.
3. S100 proteins
Calcium plays important roles in many cellular processes, such as
cell proliferation and cell death, and alterations in the calcium levels
and signaling have been observed in cancer cells. Inside the cells,
calcium-level differences can result from changes in the calcium spikes
within the cells due to variations in calcium inﬂux, efﬂux and release
from the intracellular stores. In many cell types, the store-operated cal-
cium channels (SOC), ORAI1 and STIM1, play major roles in regulating
Fig. 2. A: RAGE signaling in pancreatic cancer. In pancreatic-cancer cells, RAGE promotes
autophagy, resulting in higher cell survival and sustained RAGE activation through a NF-
κB dependent, positive feedback loop. RAGE can be activated by several ligands, including
S100P, which is produced by pancreatic-cancer cells, and HMGB1, which is released from
dying pancreatic cells following chemo- or radiotherapy. B: Proposed signaling mecha-
nisms of S100A8/A9 in pancreatic-cancer cells. S100A8/A9 could interact with RAGE, lead-
ing to the activation of MAP kinases and NF-κB signaling. Depending on the status of
Smad4 in the cells, S100A8/A9 has been shown to activate differentially AKT, NF-κB and
the mTOR signaling pathway. S100A9 may form a heterocomplex with TGF-β, resulting
in modulating the TGF-β signaling pathway. S100A9 could also promote tumor growth
through the engagement of TLR4, as demonstrated in prostate tumors.
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et al. recently showed that ORAI1 and STIM1 possessed additional
pro-survival and anti-apoptotic roles, and were up-regulated following
treatments with the cytotoxic drugs gemcitabine and 5-ﬂuorouracil [9].
Inside cells, changes in the calcium levels are sensed by calcium-
binding proteins, such as S100 proteins. These proteins form a family
that currently has 24 members [3]. The S100 genes of the A series
(S100A1 to S100A16) are located in a region of chromosome 1 which is
prone to rearrangements, linking these S100 proteins with cancer [3].
The S100 proteins bind calcium with moderate micromolar afﬁnity
(Kd), and certain S100 proteins also bind zinc and copper [3]. Because
of these moderate calcium-binding afﬁnities, in resting intracellular
conditions, S100 proteins are in the inactive conformation. However,
following calcium spikes, the intracellular calcium concentration
increases sufﬁciently to chelate the S100 proteins, resulting in confor-
mational rearrangements that allow them to interact with their target
proteins. These targets can be S100 speciﬁc or shared with other S100
proteins [10].In recent years, there has been a growing interest to understandhow
S100 proteins contribute to the progression of human cancers (see the
following reviews [11,12]). In this mini-review, we focus on S100
proteins with extracellular functions, thus we speciﬁcally examine
how S100A2, S100A4, S100A6, S100A8/A9, S100A11 and S100P
contribute to the progression of pancreatic cancer.
3.1. S100A2
Although S100A2 is mainly a nuclear protein, it translocates to the
cytoplasm and has been shown to be secreted into the extracellular
milieu by kidney's epithelial cells. We therefore brieﬂy discuss the role
of S100A2 as a potential extracellular RAGE ligand in pancreatic cancer.
S100A2 appears to have a complex role in cancer with either a tumor-
suppressor role, such as in prostate, oral, lung and breast cancers, or as
a tumor promoter in others, including esophageal squamous carcinoma,
gastric and ovarian cancer [3,11,12].
In several studies, S100A2 has been reported to be up-regulated in
pancreatic-cancer tissues, and recent clinical data suggest S100A2 to
be a predictive biomarker for pancreatic-cancer patients undergoing a
pancreatectomy or being treated with adjuvant therapy [13,14]. For
patients treatedwith adjuvant therapy, high levels of S100A2 correlated
with high overall survival [13], whereas for patients who had a pancre-
atectomy, low levels of S100A2 were shown to be predictive of better
overall survival rates after surgery, suggesting the complex roles of
S100A2 in cancer progression.
Despite the fact that S100A2 possesses mainly nuclear targets, such
as the tumor-suppressor p53 protein [3,11,12], we recently showed
that, in vitro, S100A2 can interact with RAGE [15]. This interaction still
needs to be conﬁrmed in vivo. Depending upon the signaling pathways
activated by S100A2/RAGE in pancreatic-cancer cells, S100A2 could act
as either a tumor promoter or a tumor suppressor.
3.2. S100A4
S100A4 was identiﬁed from a highly metastatic mammary carcino-
ma cell line and was, hence, named metastasin. Later studies showed
that, when S100A4 was overexpressed in cancer-cell lines, the cells
exhibited increased invasiveness and motility [3]. In addition, highly
metastatic mammary carcinoma cells showed delayed tumor growth
when implanted in S100A4 (−/−) mice, compared to their growth in
wild-type mice, further supporting the important role of S100A4 for
tumor growth. In a mouse model, S100A4 was shown to participate in
the homing of breast-cancer cells to the animal's bones [16]. Strong
correlations were found between the level of S100A4 and the prognosis
for patients carrying tumors of esophageal squamous cell carcinoma,
non-small cell lung and gastric cancers, melanoma, prostate adenocarci-
noma and bladder cancer [3,11,12].
In pancreatic cancer, S100A4 was overexpressed in a panel of 21
pancreatic-cancer cells with levels of S100A4 varying by about 1000-
fold among cell lines. In cell lines (AsPC-1 and MIA PaCa-2) expressing
the highest levels of S100A4, suppressing the S100A4 expression result-
ed in cell apoptosis anddecreasedmotility [17]. For the two cell lines ex-
pressing the lowest level of S100A4 (PCI-35 and -43), forced expression
of this S100 protein resulted in increased cell motility without changing
the proliferation or invasion properties [17]. Increased S100A4 levels
were also associated with chemoresistance and radioresistance in
pancreatic-cancer cell lines [18].
Several clinical studies have found a correlation among the
expression level of S100A4, the invasive properties of the pancreatic tu-
mors and the patients' prognosis [19,20]. Although performed with
small patient cohorts, these studies suggest that S100A4 could become
a useful prognostic marker for pancreatic-cancer patients.
S100A4 can exert intracellular and extracellular functions, all relevant
to cancer progression. The intracellular targets of S100A4 include p53,
non-muscle myosin, F-actin and tropomyosin [3,11,12]. Extracellular
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and RAGE. The interaction of S100A4with annexin II has been associated
with enhanced mechanisms of angiogenesis, such as the formation of
capillary-like tubes by endothelial cells. Angiogenesis is an important
part of tumor development, and other studies also support the role of
S100A4 in this process [3,11,12]. S100A4 has also been shown to interact
with RAGE in vitro [15] as well as to enhance the cells' motility, metasta-
ses formation and tumorigenesis in a RAGE-dependent manner in a
variety of cells and tissues, including colon- and prostate-cancer cells as
well as melanoma tissues [21–23]. It has not been demonstrated that
S100A4 triggers RAGE-dependent signaling in pancreatic-cancer cells
or tumors. At the molecular level, S100A4 expression has been shown
to be regulated by the sonic hedgehog–GLi1 signaling pathway (Fig. 3)
[24],whichplays an important role in pancreatic ductal adenocarcinoma,
and by the dual Src–FAK signaling pathway [25].
3.3. S100A6
S100A6 is another member of the S100 family with a relevance to
cancer. S100A6 was initially identiﬁed from ﬁbroblasts and has since
been found to be abundant inmany other cell types, including epithelial
cells, neurons, glial cells, smooth-muscle cells, cardiac myocytes,
platelets and lymphocytes [3,11,12]. S100A6 is up-regulated in a large
number of cancer tissues that include colorectal cancer, hepato-
cellular carcinoma, melanoma as well as lung, gastric and pancreatic
cancer [3,11,12].
Two early comprehensive gene-proﬁling studies about pancreatic
adenocarcinoma and pancreatitis tissues showed several genes speciﬁ-
cally up-regulated in pancreatic-cancer tissue; these genes included
S100A6 and S100P. In recent studies, S100A6 was shown to be a poten-
tial diagnostic marker of pancreatic ductal adenocarcinoma [26]. In
Panc-1 cells, the overexpression of S100A6 was shown to result in in-
creased migration and invasion in a β-catenin-dependent manner,
thereby inﬂuencing the epithelial to mesenchymal transition processes
[27].
S100A6 possesses both intracellular and extracellular targets. The in-
tracellular targets have been reviewed elsewhere [3,11,12]. As an extra-
cellular ligand, S100A6 has been shown to interact with and signal
through RAGE [15,28] and to interact with the integrin beta 1 receptorFig. 3. Signaling of S100A2, S100A4 and[29]. Whether the effects of S100A6 in PDAC are mediated by RAGE is
currently unknown.
3.4. S100P
S100P was initially identiﬁed from placental tissue, hence its name
[3]. Besides the placenta, S100P is also found in signiﬁcant levels in ep-
ithelial cells of the stomach [3]. Its expression signiﬁcantly increases in
many solid tumors, including ovarian, prostate, gastric, colorectal,
breast and pancreatic carcinomas [3,30]. S100P is clinically used as a di-
agnostic marker of pancreatic ductal adenocarcinoma [31,32].
S100P interacts with several intracellular and extracellular target
proteins. Intracellular targets include ezrin, the Ras GTPase activating-
like protein1 (IQGAP1) and a protein named the S100P binding protein
(S100PBP), all relevant with pancreatic cancer [3,11,12].
Extracellular S100Pwas shown tobind to RAGE [33] and to stimulate
cell-growth survival and invasion (Fig. 2A) [30]. As a result, several
RAGE/S100P inhibitors were developed and used to block RAGE-
dependent, pancreatic-cancer cell or tumor growth [7,30,34–37]. A
S100P-derived peptide, which blocks the RAGE/S100P interaction,
inhibited pancreatic-tumor growth and metastasis formation in a
pancreatic ductal adenocarcinoma mouse model [30,34]. Different
forms of cromolyn, 5-methyl cromolyn and cromolyn encapsulated
into liposomes [35], were shown to reduce pancreatic-tumor growth
in mice [7,36]. Recently, Dakhel et al. showed that monoclonal antibod-
ies against S100P could also reduce pancreatic-cancer cell growth and
metastasis formation in a xenograft mouse model [37].
3.5. S100A8 and S100A9
S100A8 and S100A9 are mainly expressed as S100A8/A9 heterodi-
mers [3]. S100A8/A9 are often referred to as cytokines because, in cer-
tain inﬂammatory conditions, they are abundantly secreted by
immune cells, speciﬁcally neutrophils [3]. S100A8/A9 have also been
shown to be expressed by tumor and non-tumor cells in cancer tissues
and to modulate tumor growth and metastasis [3].
Extracellular S100A8 and S100A9 homodimers or S100A8/A9 het-
erodimers have been shown to interact with several cell-surface mole-
cules, including TLR-4; EMMPRIN; the scavenging receptor, CD36; andS100A6 in pancreatic-cancer cells.
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shown to promote tumorigenesis in a colitis-induced colon-cancer
mouse model as well as to increase the proliferation of colon- and
breast-cancer cells [3,11,12,38]. In the lungs, S100A8 has been shown
to favor the homing of metastatic cells by locally enhancing vascular
permeability [39].
S100A8 and S100A9 were shown to contribute to pancreatic-cancer
progression. In one study, higher levels of S100A8 were found in pan-
creatic ductal adenocarcinoma compared to normal and pancreatitis tis-
sues. A subsequent proteomic study revealed that, in pancreatic tumors,
the level of both S100A8 and S100A9 varied according to the expression
level of the tumor-suppressor Smad4 protein [40]. In another study, a
detailed analysis of the signaling pathways regulated by S100A8 and
S100A9 in pancreatic tumors showed different modes of NF-κB and
AKT regulation, depending on the expression of Smad4 [41]. Smad4 is
a key transcription factor in the TGF-β signaling pathways, 1 of 12
core pathways that is deregulated in pancreatic adenocarcinomas [42].
Using pancreatic-cancer cells (Panc-1) in a culture, Ang et al. showed
that, when stimulating the cells with recombinant S100A8, S100A9
resulted in increased cell migration [43] and that the increased migra-
tion by S100A8 could be reverted when Smad4 was knocked down by
siRNA [43]. In a different study, it was shown that deleting Smad4 in
pancreatic-cancer cells resulted in a higher expression of S100A8/A9,
leading to increased levels of myeloid-derived suppressor cells
(MDSCs) and advanced stages of PDAC [44]. In addition, in prostate can-
cer, S100A9 was shown to promote tumor growth through the activa-
tion of TLR4 [45]. Signaling crosstalks among the RAGE, TLR4, TGF-β
and Smad4 pathways could, thus, take place in pancreatic-cancer cells
(Fig. 2B) [46]. S100A8 and S100A9 measured in the pancreatic main-
duct ﬂuid were suggested to serve as prognostic biomarkers [47].
3.6. S100A11
S100A11 is another member of the S100 protein family that is pres-
ent in a large number of tissues but is more abundantly expressed in
smooth muscle. S100A11 was studied, in detail, in chondrocytes
where it acted as a catabolic cytokine. Like S100A2, S100A11 was
shown to play the role of a tumor suppressor, such as in bladder or
renal carcinoma, or as a tumor promoter, such as in pancreatic cancer
[3,11,12]. It was shown that the levels of S100A11 increased during
the early stages of pancreatic cancer but decreased during the advanced
stages of pancreatic cancer [48]. Interestingly, it was also reported that
high expression levels of S100A11 in pancreatic ductal adenocarcinoma
are associated with an unfavorable prognosis for patients who had un-
dergone surgical resection [49]. Several target proteins were described
for S100A11: the tumor-suppressor p53 protein; members of the
annexin family (annexin 1 and 2); the DNA repair protein, RAD54B;
and RAGE [3,11,12]. Although S100A11 was associated with RAGE
signaling in chondrocytes, a direct interaction between RAGE and
S100A11 as well as a role for S100A11/RAGE signaling in PDAC have
yet to be demonstrated.
4. Conclusion and therapeutic approaches
Recently, RAGE has emerged as a new therapeutic target. Several
small molecular inhibitors, such as TTP488, have been developed [50].
In pancreatic cancer, current efforts aim at speciﬁcally targeting the
RAGE/S100P interaction. The small molecule cromolyn and its deriva-
tives have shown encouraging results in mouse models of the disease
[7,36]. A S100P-derived peptide has also shown efﬁcacy in mice
[30,34]. Another therapeutic approach consists of targeting S100 pro-
teins with monoclonal antibodies. Recent studies have shown that
treatment with anti-S100P or anti-S100A4 antibodies could effectively
reduce the tumor's growth and the formation of metastases in mouse
models of pancreatic cancer [37]. In conclusion, blocking the RAGE/S100 ligand axis appears to be a promising, new therapeutic approach
to treat pancreatic ductal adenocarcinoma.
In pancreatic cancer, the expression of S100A2, S100A4 and S100A6
has been shown to be regulated by the transcription factor, GLi1, an im-
portant downstream element of the sonic hedgehog pathway that has
been implicated in pancreatic ductal adenocarcinoma. The sonic hedge-
hog homolog (SHH) protein binds to its receptor, Patched (PTCH1),
which leads to the release of inhibition of the receptor smothered
(SMO) and the translocation to the nucleus of the glioma-associated
oncogene homolog 1 (GLI1) transcription factor. GLI1 controls the ex-
pression of S100A2, S100A4 and S100A6. These S100 proteins can inter-
act with p53 and can also modulate its transcriptional activity.
Alternatively, S100 proteins can be released in the extracellular media
and interact with RAGE at the cell surface. RAGE engagement by the
S100 proteins can lead to the activation of several MAP kinases,
resulting in the transcription of NF-κB regulated genes, including RAGE.
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